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Primary Care and Public Health, Blizard Institute, Queen Mary University of London, London, UKA B S T R A C TBackground: Estimating individual-level medication costs in an eco-
nomic evaluation can involve extensive data collection and handling.
Implications of detailed versus general approaches are unclear.
Objectives: To compare costing approaches in a trial-based economic
evaluation. Methods: We applied four costing approaches to pre-
scribed medication data from the Tumour necrosis factor inhibitors
Against Combination Intensive Therapy randomized controlled trial.
A detailed micro-costing approach was used as a base case, against
which other approaches were compared: costing medications used by
at least 1.5% of patients; costing medications on the basis of only
chemical name; applying a generic prescription charge rather than a
medication-speciﬁc cost. We quantitatively examined resulting esti-
mates of prescribed medication and total care costs, and qualitatively
examined trial conclusions. Results: Medication costs made up 6% of
the total health and social care costs. There was good agreement in
prescribed medication costs (concordance correlation coefﬁcient [CCC]
0.815, 0.819, and 0.989) and excellent agreement in total costsee front matter Copyright & 2018, International S
r Inc. This is an open access article under the CC
ons.org/licenses/by-nc-nd/4.0/).
1016/j.jval.2017.02.001
t.heslin@kcl.ac.uk.
ondence to: Margaret Heslin, King’s Health Econo
De Crespigny Park, Denmark Hill, Box 024, Londo(CCC 0.990, 0.995, and 0.995) between approaches 1 and 2. Approaches
3 and 4 had poor agreement with approach 1 on prescribed medication
costs (CCC 0.246–0.700 and 0.033–0.333, respectively), but agreement on
total care costs remained good (CCC 0.778–0.993 and 0.729–0.986,
respectively). Conclusions: Because medication costs comprised only a
small proportion of total costs, the less resource-intensive approaches
had substantial impacts on medication cost estimates, but had little
impact on total care costs and did not signiﬁcantly impact the trial’s
cost-effectiveness conclusions. There is room for research efﬁ-
ciencies without detriment to an evaluation in which medication
costs are likely to form a small proportion of total costs.
Keywords: costs, economic, medication, trial.
Copyright & 2018, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Central to conducting an economic evaluation is the identi-
ﬁcation, measurement, valuation, and comparison of the costs
and consequences of the alternatives being considered [1].
Once resources have been identiﬁed and measured, valuation
needs to be completed to provide a cost. Deciding on which
costing approach to adopt in an economic evaluation is just as
important as deciding what costs to include [1]. The aim of the
study, type of patient group, disorder under investigation,
treatment comparison, setting, and many more factors will
contribute to decisions on how to approach unit costing. Cost-
ing medications in economic evaluations can take a consid-
erable amount of time and effort [1]. Individual-level micro-
costing (using all detailed information on the resources used)
is the most accurate method with more macro-costingapproaches (using general or aggregate valuations) becoming
progressively less accurate. The National Institute for Health
and Care Excellence (NICE) guide to the methods of technology
appraisal 2013 [2] provides methodological recommendations
for economic evaluations and recommends that costs should
be based on the drug tariffs for medications that are predom-
inantly prescribed in primary care. The International Society
for Pharmacoeconomics and Outcomes Research guidelines
state that “[d]rug cost values and measurements should be
transparent and made available to any reader or user of a CEA,”
but do recommend how costs should be applied to resource use
data [3]. There is variation in approaches taken across eco-
nomic evaluations, with consequent variations in research
effort and resourcing. The value of detailed micro-costing,
and consequences of less accurate approaches, for an evalua-
tion is unclear.ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
BY-NC-ND license
mics, Institute of Psychiatry, King’s College London, The David
n SE5 8AF, UK.
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care and care costs. For many health conditions, medications
constitute a small fraction of the total health care cost. For
example, the cost of medication in the treatment of schizophre-
nia has been estimated to account for 2% of direct costs [4]; in
multiple sclerosis this is estimated as 8.1% of total costs [5], 13%
in lower back pain [6], and less than one-quarter in inﬂammatory
bowel disease [7]. For coronary heart disease, the leading single
cause of death in the United Kingdom, the cost of medication has
been estimated at only 32% of total health care costs [8].
In these circumstances, when medications represent a very
small to moderate proportion of the total direct costs, it is easy to
see why a more macro approach to medication costing might be
taken, because the impact of imprecision will be minimal in the
context of total costs. Nevertheless, when medication is the
mainstay of treatment, for example, in chronic conditions with-
out cure (e.g., in moderate to severe chronic psoriasis vulgaris in
which medications make up 60% of direct costs [9]), or when
medications are particularly expensive, they become a major cost
driver in the context of total costs. There are also complications
when valuing medications as compared with other types of
resources in an economic evaluation because of issues around
value and cost [10], but that is beyond the scope of this study.
Using data from a completed within-trial economic evaluation
involving participants with rheumatoid arthritis [11,12]—care of
which is heavily reliant on management by medication and
associated with cost pressures arising from newer, more expen-
sive medications—we applied a number of alternative approaches
to costing medication. We then examined the impact of this on 1)
total medication costs, 2) total health and social care costs, and 3)
the conclusions of the trial.Methods
Data Sources
We used data from the TACIT trial [11,12]. In brief, the Tumour
necrosis factor inhibitors Against Combination Intensive Therapy
(TACIT) trial was an open-label, multicenter, randomized con-
trolled trial conducted over 12 months in the United Kingdom.
Twenty-four clinics recruited patients with active rheumatoid
arthritis who met UK criteria for accepting tumor necrosis factor
inhibitors (TNFis). Patients were randomized to a treatment
strategy of starting either TNFis or conventional disease-
modifying antirheumatic drugs (cDMARDs). At 6 months, partic-
ipants who had not responded adequately to the medication
were switched either to another TNFi or, in the case of partic-
ipants allocated to the cDMARDs arm, to their ﬁrst TNFi.
The trial included a concurrent economic evaluation. It
measured costs from health and social care as well as societal
perspectives and linked them with Health Assessment Question-
naire (HAQ) scores and quality-adjusted life-years (QALYs) (on
the basis of both the short form 36 health survey [SF-36] and the
three-level EuroQol ﬁve-dimensional questionnaire [EQ-5D-3L]) at
both 6 and 12 months. All resource use was collected using an
adapted version of the Client Service Receipt Inventory (CSRI;
collected at baseline, 6 months, and 12 months) retrospectively
for 3-month periods and extrapolated up to 6-month periods,
except trial medications. The CSRI included health and social
care costs: inpatient services, outpatient services, primary care
services, other community-based services, social services, and
other prescribed nontrial medications. Trial medications were
recorded separately and prospectively by clinical and research
staff over the entire study period using a speciﬁcally designed
proforma. Details of medication resource use included medica-
tion name, dose, frequency, and duration of use. For estimatingcosts associated with medications, only generic medication
names were taken into account to ensure cost estimations were
conservative. All costs are reported in pounds sterling at 2010/
2011 prices. Discounting was not necessary because all costs were
related to a 1-year period.
In the further analyses reported here, we examine ﬁndings
only in relation to the health and social care perspectives because
the inﬂuence of medication costs on total costs would likely be
more visible than when applying to more comprehensive per-
spectives. In addition, this is the perspective currently preferred
by NICE in its decision making [2].
In this trial there were two sets of medication data collected:
the medication given as part of the trial designated by interven-
tion/control status and all other medications taken for reasons
not linked to the trial. It is recommended that the intervention in
an economic evaluation be always micro-costed [13]; therefore,
we micro-costed the intervention medications as was done in the
trial. This is included along with other components in the total
health and social care costs. In the comparison of costing
approaches, we focused solely on other medications that were
prescribed independently from the trial. Because the trial med-
ications were limited to a handful, these were less resource-
intensive to value and cost compared with other prescribed
medications. In the comparisons, all other cost components were
held constant and only the nontrial prescribed medication cost-
ing approaches were varied as described herein.
Costing Approaches
The following four costing approaches were selected for compar-
ison. These are summarized in Table 1.
Approach 1: Cost per milligram (base-case analysis)
This criterion standard micro-costing approach [1] was used for
the economic evaluation in the TACIT trial [11,12]. A unit cost for
each medication was calculated in the form of a cost per milli-
gram. This was calculated on the basis of the most cost-efﬁcient
pack size, choosing maintenance prices over initial treatment
prices and generic prices over branded ones to obtain conserva-
tive estimates. These were based on the recommended dose
provided by the British National Formulary [14], which is a
reference book that contains information and prices of medica-
tion available on the National Health Service. These unit costs
were then applied to the data by multiplying the cost per milli-
gram by the dose reported, the number of doses per day, and the
number of days used. A series of rules were applied to address
missing data in a standardized way. When medication name was
missing but other information (e.g., dose) indicated some use, a
standard charge based on the prescription cost analysis (PCA)
was applied [15]. When a medication name was provided but unit
quantity was missing, a cost based on the lowest cost chemical
name for that medication from the PCA [15] (or based on the
lowest cost individual preparation when chemical name was not
available) was applied. When the number of days of use was
missing, a PCA cost was used, and the patient was assumed to
have received the item once in that period. If patients reported
that the frequency of use was “as necessary,” it was assumed that
the patient received one prescription during the time period.
Approach 2: 1.5% of medications
The second approach used the same micro-costing approach as
approach 1 but with an emphasis on the more commonly used
medications across the sample. This approach was used by
McCrone et al. [16] as a practical approach, given that the service
users for their study recorded approximately 1000 medication
names. Only those medications that were used by at least 1.5% of
Table 1 – Details of the four costing approaches.
Costing method Prescribed medication Missing data protocol
Approach 1
(Cost per milligram)
This was used as the
base-case analysis,
which other
approaches will be
compared against
 Cost calculated per milligram on the basis of most
efﬁcient pack size
 Maintenance prices chosen
 Generic prices chosen
 On the basis of recommended dose from BNF (If
recommended dose given for rheumatoid arthritis,
choose this over other recommended doses)
 Cost per milligram  dose  doses taken per day 
number of days taken in period
 Use route/preparation stated by patient
 For all creams/ointments, assume one tube lasts a
month and use the smallest tube
 For dual medications, with milligram and
microgram combo drugs, count only the milligrams.
If combo of milligram and milligram, add them
together
Partial data missing:
 If medication name is missing but other
information available, standard charge based on
PCA is used.
 If unit quantity is missing but medication name is
available, cost based on the lowest cost chemical
name for that medication from PCA is used, or cost
based on PCA charge is used when chemical name is
unavailable.
 If medication dose is missing, apply the PCA average
cost for that drug, assuming each prescription lasts
1 mo or use overall charge if speciﬁc medication is
not available.
 If no route/preparation is given by patient, use what
seems most appropriate on the basis of dose, but
prioritize tablets and capsules.
 If the number of days of medication use is missing,
use a PCA item cost and assume that the patient got
the item once in that period.
 If frequency is “as necessary,” number of days of
medication use in each period is missing, use a PCA
cost for that drug and assume that the patient got
one prescription in each time point.
Approach 2
(1.5% of medications)
 Only medications used by 41.5% of micro-costed
 Cost calculated per milligram on the basis of most
efﬁcient pack size
 Maintenance prices chosen
 Generic prices chosen
 On the basis of recommended dose from the BNF
 Cost per milligram  dose  doses taken per day 
number of days taken in period
As in approach 1.
Approach 3
(Costing according to
chemical name)
 Cost is calculated according to PCA charge per item
on the basis of chemical name as recorded in
the BNF
 When there are different costs attached to the
chemical names, a weighted average will be taken
 Assume any PCA charge is 1 month’s worth of
medication
Partial data missing:
 If medication brand is needed but not speciﬁed and
there are multiple chemical name options in the
PCA, a weighted average will be taken.
 If medication name is missing but other
information is available, use standard PCA charge.
 If unit quantity is missing but medication name is
available, cost based on the lowest cost chemical
name for that medication from PCA is used, or cost
based on PCA charge is used when chemical name is
unavailable.
 If the number of days of medication use is missing,
assume that the patient got the item once in that
time period.
 If frequency is “as necessary,” the number of days of
medication use in each period is missing, assume
that the patient got one prescription in each
time point.
Approach 4
(Prescription charge
analysis)
 Cost calculated by applying standard charge per
item on the basis of PCA
 Assume any PCA charge is 1 month’s worth of
medication
Partial data missing:
 If the number of days of medication use is missing,
assume that the patient got the item once in that
time period.
 If frequency is “as necessary,” the number of days of
medication use in each period is missing, assume
that the patient got one prescription in each
time point.
BNF, British National Formulary; PCA, prescription cost analysis.
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Table 2 – Mean and comparison of prescribed medication costs at each time point for each of the costing
approaches.
Time
point
Prescribed medication
cost (£), mean  SD
Mean
difference
95%
conﬁdence
interval for
difference
Paired
sample
t test
Correlation
concordance
coefﬁcient
95%
limits of
agreement
Approach 1 Approach 2
Baseline
(n ¼ 205)
172  211 144  167 28 12 to 43 3.521, P o 0.001 0.815 249, 194
6 months
(n ¼ 191)
95  226 63  176 33 16 to 49 3.962, P o 0.001 0.819 264, 199
12 months
(n ¼ 188)
236  898 200  891 35 18 to 53 3.907, P o 0.001 0.989 290, 219
Approach 1 Approach 3
Baseline
(n ¼ 205)
172  211 132  120 40 17 to 63 3.453, P o 0.001 0.520 365, 285
6 months
(n ¼ 191)
95  226 89  158 7 14 to 28 0.647, P ¼ 0.518 0.700 303, 290
12 months
(n ¼ 188)
236  898 127  265 108 3 to 220 1.913, P ¼ 0.057 0.246 1699, 1482
Approach 1 Approach 4
Baseline
(n ¼ 205)
172  211 133  85 39 13 to 64 3.0122, P ¼ 0.003 0.333 400, 322
6 months
(n ¼ 191)
95  226 99  85 3 32 to 25 0.234, P ¼ 0.815 0.258 405, 412
12 months
(n ¼ 188)
236  898 101  85 135 13 to 257 2.179, P ¼ 0.031 0.033 1873, 1603
*Covers a 3-mo period.
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medication resource use with missing medication names could
not be included in this approach. Unit cost calculations and
approaches to missing data were the same as in approach 1.
Approach 3: Chemical name
The third approach is one used by Powell et al. [17]. This involves
costing all medications but calculating unit costs differently. Unit
costs were calculated for each medication by looking up the cost
of a prescription for that medication’s chemical name according
to the PCA. An arbitrary assumption was made that one PCA
prescription charge represents 1 month’s worth of medication.
The number of PCA charges assigned to each medication was
based on the number of days of use reported by the patient. For
example, if a patient took a medication for up to and including
30 days, we took this to indicate one prescription and therefore
one prescription charge. Accordingly, we assumed that 31 to 60
days of use indicated two prescriptions and 61 to 90 days of use
indicated three prescriptions. The number of prescription charges
was then multiplied by the chemical name net ingredient cost of
the medication. When a medication brand was not speciﬁed and
multiple chemical names were offered in the PCA, an overall
average PCA charge was applied. When medication names were
missing but other information was available, for example, num-
ber of days of medication use, a standard PCA charge was used. If
the unit was missing but the medication name was given, the
cost was generated on the basis of the lowest cost chemical name
for the medication provided from the PCA. When the number of
days of medication use was missing, an assumption was made
that the patient received the item once during the time period.
When frequencies were reported as “as necessary,” anassumption was made that the patient received one prescription
during the time period.
Approach 4: Prescription charge analysis
The ﬁnal approach is the most macro approach, which was used
in the valuation of some medications by Amiel et al. [18]. The unit
cost of each medication was taken as an overall total PCA charge
per item. This is the net ingredient cost average for all medi-
cations listed in the PCA (£9.16). As with approach 3, the PCA
charge was multiplied by the number of days of medication use
(0–30 days assumed to be one prescription, 31–60 days indicating
two prescriptions, and 61–90 days indicating three prescriptions)
to give the medication costs, and missing medication name or
days on medication were dealt with as in approach 3.
Analysis
Data were analyzed using STATA 11 (StataCorp LP, College
Station, TX). Taking the base-case approach as a comparator,
we compared each approach’s respective impacts on estimates of
total medication costs, estimates of total health and social care
costs, and the resulting cost-effectiveness conclusions of
the study.
The total mean cost of prescribed medications produced by
each approach was compared using paired sample t tests (con-
ﬁrmed by Wilcoxon rank sum tests to account for non-normal
distribution). Overall agreement was measured using the Lin
concordance correlation coefﬁcient (CCC) and limits of agreement
[19], which has been shown to be a more appropriate measure
than the Pearson correlation [17,19,20]. A CCC of 1 indicates
perfect agreement and of –1 indicates perfect inverse agreement.
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to 79% is fair, 80% to 89% is good, and 90% to 100% is excellent.
Total health and social care costs produced by each costing
approach are also compared using paired sample t tests and
CCCs. Incremental cost-effectiveness ratios (ICERs)/incremental
cost-utility ratios were calculated on the basis of the resultant
health and social care costs from each approach. Because the
resource use data were recorded for a 3-month (rather than a
6-month) period at each follow-up point, the associated cost data
were multiplied by 2 to extrapolate to a full 12-month period as
per the approach used in the TACIT trial base-case economic
evaluation. Cost-effectiveness acceptability curves (CEACs) based
on the net-beneﬁts approach were also created to explore
uncertainty. Estimates of mean costs and outcomes used to
calculate ICERs included covariates for baseline HAQ score,
duration of illness, age, sex, region, ethnicity, and baseline
costs/outcome as appropriate.Results
Sample
The results reported are based on the 205 patients recruited and
randomized in the trial of which 152 (74%) were female, 181 (88%)
were of white ethnic origin, and mean age was 57 11.97 years. The
mean duration of illness was 8  8.82 years. Of the 205 patients, all
(100%) had CSRI data (and therefore prescribed medication data)
available at baseline, 191 (93%) at 6 months, and 188 (92%) at
12 months. Only these patients with prescribed medication andFig. 1 – Histograms showing the distribution of medichealth and social care use data were included in the comparisons of
costs. Some of these participants, however, had missing outcomes
data and so were not included in subsequent comparisons of cost-
effectiveness estimations. The lowest number of participants
included in any cost-effectiveness analysis, because they had both
cost and outcome data, was 186 out of 205 (91%).
Impact on Prescribed Medication Cost Estimates
The mean costs of the prescribed medications at each time point
for each of the costing approaches are presented in Table 2. We
have presented the mean costs of the prescribed medications for
the intervention and control arms combined, because the focus is
to compare costing approaches (see Scott et al. [12] for economic
evaluation trial results). It appears that the medication costs drop
dramatically between baseline and 6-month follow-up. This is
because medication at baseline is included in the prescribed
medication category, whereas at 6 months, medication is divided
into prescribed medication and trial medication. The mean cost
of prescribed medication at baseline was £172  £211 on the
basis of approach 1 compared with £144  £167, £132  £120, and
£133  £85 on the basis of approaches 2, 3, and 4, respectively.
This was lower at 6 months with a mean cost of prescribed
medication of £95  £226 on the basis of approach 1 compared
with £63  £176, £89  £158, and £99  £85 on the basis of
approaches 2, 3, and 4, respectively. At 12 months, these were
£236  £898, £200  £891, £127  £265, and £101  £85 on the
basis of approaches 1, 2, 3, and 4, respectively.
Results indicate that although there is a statistically signiﬁ-
cant difference in prescribed medication costs produced byation costs using each costing approach (baseline).
Table 3 – Mean and comparison of health and social care costs at each time point for each of the costing
approaches (including all medications).
Time
point
Health and social care cost*
(£), mean  SD
Mean
difference
95%
conﬁdence
interval for
difference
Paired sample
t test
Correlation
concordance
coefﬁcient
95%
limits of
agreement
Approach 1 Approach 2
Baseline
(n ¼ 205)
1335  1665 1279  1639 56 24 to 87 3.521, P o 0.001 0.990 499, 388
6 months
(n ¼ 191)
3417  2570 3348  2542 69 35 to 104 3.925, P o 0.001 0.995 548, 410
12 months
(n ¼ 188)
3781  2798 3705  2788 76 37 to 115 3.829, P o 0.001 0.995 606, 455
Approach 1 Approach 3
Baseline
(n ¼ 205)
1335  1665 1255  1644 80 34 to 125 3.453, P o 0.001 0.979 729, 569
6 months
(n ¼ 191)
3417  2570 3403  2623 14 31 to 59 0.615, P ¼ 0.539 0.993 628, 600
12 months
(n ¼ 188)
3781  2798 3544  2300 236 7 to 480 1.914, P ¼ 0.057 0.778 3556, 3083
Approach 1 Approach 4
Baseline
(n ¼ 205)
1335  1665 1257  1645 78 27 to 128 3.0122, P ¼ 0.003 0.974 800, 645
6 months
(n ¼ 191)
3417  2570 3423  2573 6 67 to 56 0.185, P ¼ 0.854 0.986 841, 852
12 months
(n ¼ 188)
3781  2798 3484  2247 297 31 to 563 2.202, P ¼ 0.029 0.729 3923, 3329
* Health and social care costs include nonmedication costs, prescribed medication, and trial medications. Costs are extrapolated up to 6-mo
periods (except trial medications that covered 6 mo).
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3.521, P o 0.001; t ¼ 3.962, P o 0.001; t ¼ 3.907, P o 0.001,
respectively), there is still a good to excellent level of agreement
(CCC 0.815, 0.819, and 0.989, respectively). In contrast, the comparison
of approach 1 with approaches 3 and 4 shows poor agreement at
baseline, 6 months, and 12 months (CCC 0.520, 0.700, and 0.246,
respectively, for approach 3 and CCC 0.333, 0.258, and 0.033,
respectively, for approach 4). In Figure 1, we have presented four
overlapping histograms in addition to show the distribution of
medication costs for each costing approach. The distribution
shows that as we move from approach 1 to approaches 2, 3, and
4, the few cases with larger costs become less and the frequency
of the lower costs increases. This is for baseline data, but similar
patterns were found for 6-month and 12-month data also.Impact on Health and Social Care Cost Estimates
The mean health and social care costs at each time point for each
of the costing approaches are presented in Table 3. For each
approach, the prescribed medications made up the following
proportions of the total health and social care costs at baseline, 6
months, and 12 months: 11% to 13%, 2% to 3%, and 3% to 6%,
respectively.
At 6 months, mean health and social care costs were £3417 
£2570 on the basis of approach 1 compared with £3348  £2542,
£3403  £2623, and £3423  £2573 on the basis of approaches 2, 3,
and 4, respectively. At 12 months, these were £3781  £2798,
£3705  £2788, £3544  £2300, and £3484  £2247 on the basis of
approaches 1, 2, 3, and 4, respectively.
There was little variation across all approaches within each time
point. The mean difference between approaches 1 and 2 is verysmall for all three time points and again results indicate that
although there is a statistically signiﬁcant difference in prescribed
medication costs produced by approaches 1 and 2 at baseline, 6
months, and 12 months (t ¼ 3.521, Po 0.001; t¼ 3.925, Po 0.001; t¼
3.829, P o 0.001, respectively), there is still an excellent level of
agreement (CCC 0.990, 0.995, and 0.995, respectively).
The comparison of approaches 1 and 3 and approaches 1 and
4 shows excellent agreement at baseline and 6 months (CCC 0.979
and 0.993, respectively, for approach 3 and CCC 0.974 and 0.986,
respectively, for approach 4), whereas the 12-month comparison
shows a poor level of concordance (CCC 0.778 for approach 3 and
CCC 0.729 for approach 4).Impact on ICER Estimates
ICERs based on the HAQ at 6 months suggest an ICER between
£51,643 and £53,363, with approach 1 and approach 4 producing
the lowest and the highest estimates, respectively (Table 4). ICERs
based on the HAQ at 12 months ranged between £11,780 and
£12,605, with approach 3 and approach 2 producing the lowest
and the highest estimates, respectively. All ICERs based on QALYs
suggest that cDMARDS are more likely to be cost-effective
compared with TNFis (according to NICE’s recommendation of
£20,000–£30,000 per QALY). ICERs based on 6-month data (from
either the EQ-5D-3L or the SF-36) ranged from £3,615 to £3,735,
with approach 1 and approach 4 producing the lowest and the
highest QALYs, respectively. On the basis of 12-month data,
approach 3 and approach 2 produced the lowest and the highest
ICERs, with the SF-36–derived ICERs ranging from £188,480 to
£201,672 and the EQ-5D-3L–derived ICERs ranging from
£94,240 to £100,836.
Table 4 – Cost-effectiveness and cost-utility summaries at 6 mo and 12 mo on the basis of each of the four
approaches.
Time point/approach Cost per additional point
on the HAQ (£)
Cost per additional QALY
(SF-36–based) (£)
Cost per additional QALY
(EQ-5D-3L–based) (£)
6 months
Approach 1 51,643 3615 3615
Approach 2 52,509 3676 3676
Approach 3 53,238 3727 3727
Approach 4 53,363 3735 3735
12 months
Approach 1 12,063 193,000 96,500
Approach 2 12,605 201,672 100,836
Approach 3 11,780 188,480 94,240
Approach 4 12,037 192,587 96,293
EQ-5D-3L, three-level EuroQol ﬁve-dimensional questionnaire; HAQ, Health Assessment Questionnaire; QALY, quality-adjusted life-year;
SF-36, short form 36 health survey.
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CEACs based on QALYs (derived from either the EQ-5D-3L or the
SF36) showed that the probability that the cDMARDs group is
cost-effective compared with the TNFis group from a health and
social care perspective is 99% or higher at all willingness-to-pay
thresholds on the basis of all four costing approaches. Equivalent
probabilities based on the HAQ were 100% for thresholds of up to
£10,000 per point improvement on the HAQ but decreased at
higher willingness-to-pay thresholds, to around 45% at a thresh-
old of £50,000. This was true for all four costing approaches.
At 12 months, all CEACs based on all approaches suggested
that cDMARDs have a 99% or higher probability of being cost-
effective compared with TNFis at all willingness-to-pay values of
up to £50,000.Discussion
Because the medication costs comprised only a small proportion
(6%) of total costs, the less resource-intensive approaches had
substantial impacts on estimates of medication costs, but had
little impact on total care costs and thus did not signiﬁcantly
impact on the trial’s cost-effectiveness conclusions.
There was good agreement in prescribed medication costs
between the cost per milligram approach (approach 1) and the
1.5% of medications approach (approach 2) but not between the
chemical name approach (approach 3) and the prescription
charge analysis approach (approach 4) compared with the cost
per milligram approach (approach 1). On this basis one might
conclude that the 1.5% of medications approach is the only
approach that could be reliably used in lieu of the criterion
standard cost per milligram approach. Nevertheless, with the
1.5% of medications approach, there is a risk of excluding high-
cost medications used by a few participants that may in total
amount to more expense than low-cost medications used by
many. Agreement on health and social care costs remained good
to excellent between approach 1 and all other approaches. Hence,
the impact of differences in prescribed medication costs on
health and social care costs was low. This is because prescribed
medication costs were a small proportion of the overall health
and social care cost (6%). Subsequently, there were inconse-
quential impacts of the different costing approaches on the
ICERs, CEACs, and the conclusions of the study.
The results support the argument that if medication costs
were a large proportion of the overall cost, then approaches 3 and4 may not be appropriate. Furthermore, in approaches 3 and 4,
detail is lost on the more expensive drugs used by patients. A
drug that has a cost of over £1000 becomes less than £10 when
using approach 4. Therefore, in studies that include high-cost
medications, gross underestimation can occur.
It is notable that although high correlations are reported for
most approaches, the paired sample t tests indicated that the
approaches are signiﬁcantly different (in most cases). The CCC
and t test results have different meanings, and hence they do not
necessarily support one another. The CCC indicates that the cost
values are moving in the same overall direction; it shows
whether the approaches have positive values or negative values.
Here there is an acceptance that the measures are not expected
to be exactly the same, but it deciphers whether the effects are
parallel to one another and whether the change is alike. The
paired t test looks for the values to be exactly the same, and
therefore it will conﬁrm that the approaches are signiﬁcantly
different because the values cannot be exactly the same given the
different methodology. Therefore, the results from the t tests do
not undermine the results from the CCC but indicate some level
of difference between comparisons.
No other research has compared different approaches for
costing medication. Nevertheless, previous research comparing
two methods of collecting resource use data in primary care
(general practitioners’ case records and a self-complete postal
questionnaire) has reported a CCC of 0.756 as good and concludes
that either can be used without undermining the data quality
[22]. With all CCCs between the cost per milligram approach and
the 1.5% of medications approach being more than 0.9, this
consistency is even higher.
The problem of missing data is frequent in cost-effectiveness
analyses [23,24] because of issues with medication misspelling
and/or phonetic pronunciation, poor recall around medication
name, dose start and end dates, and frequent dose changes.
Medication costing and approaches to handling missing medi-
cation data are intertwined as demonstrated here, and Faria et al.
[23] have suggested appropriate ways to deal with such missing
data. Nevertheless, perhaps the key to dealing with these issues
is to mitigate for these problems earlier in the research process in
terms of greater attention to what data are collected and how.
Prospectively completed patient diaries and administrative data-
bases are alternatives that may provide fuller data compared
with retrospective self-reports of medication use. There are,
however, trade-offs to be made. For example, diaries may
potentially be more reliable for those who complete them but
they still carry a risk of complete nonresponse, and
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reliability may carry greater research burdens (e.g., people with
psychosis could be prescribed/provided with medication from
hospital pharmacies, community mental health teams, or general
practitioners, all of whom have separate databases with different
mechanisms for medication recording). Nevertheless, our study
suggests that if medication costs are likely to be a small
proportion of total costs, a detailed costing approach may not
be needed, which would reduce the amount of data needed. This
could allow patients to report much less and simpler details
about their medication usage.
This is a single study based on one trial and economic
evaluation in one disease area. Further research on the impact
of costing medications should be undertaken, particularly in
diseases for which prescribed medication plays a large part in
overall costs. Furthermore, medication data in this study were
collected using the nongeneric name of drugs. This could have
led to underestimates in drug costs from approaches 1 and 2,
which may have driven costs in these approaches down, com-
pounding differences in ﬁndings between approach 1 and
approaches 3 and 4. In addition, participants lost to follow-up
may have had medication use that was different from those who
were followed-up and may have skewed results. This needs to be
explored in further studies.
This study has indicated that a range of alternative and
possibly more efﬁcient costing approaches for medications, other
than micro-costing, are able to generate the same conclusions for
cost-effectiveness and cost-utility analyses. This is likely depend-
ent on the level of contribution that medications make to overall
care and care costs. The conclusions for the TACIT economic
evaluation remain unchanged when different prescribed medi-
cation and health and social care costs are substituted. Although
researchers should carefully consider appropriate costing
approaches in each situation, there is scope for research efﬁcien-
cies when medication costs are likely to be overshadowed by
other care costs.Acknowledgments
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